Seng Gee Lim
- Hepatology top 0.02%
- Hepatitis C virus research 141
- Liver Disease and Transplantation 25
- Hepatitis Viruses Studies and Epidemiology 19
- Epidemiology top 0.05%
- Hepatitis B Virus Studies 146
- Liver Disease Diagnosis and Treatment 103
- Infectious Diseases top 0.5%
- SARS-CoV-2 and COVID-19 Research 19
- Viral gastroenteritis research and epidemiology 18
- Virology top 2%
- Immunology top 2%
-
- Organ Transplantation Techniques and Outcomes 22
Seng Gee Lim
272 papers receiving 14.2k citations
Hit Papers
Peers
Comparison fields: 5 of 149
- Hepatology 9.2k
- Epidemiology 9.6k
- Infectious Diseases 2.8k
- Virology 306
- Immunology 1.2k
Countries citing papers authored by Seng Gee Lim
This map shows the geographic impact of Seng Gee Lim's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Seng Gee Lim with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Seng Gee Lim more than expected).
Fields of papers citing papers by Seng Gee Lim
This network shows the impact of papers produced by Seng Gee Lim. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Seng Gee Lim. The network helps show where Seng Gee Lim may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Seng Gee Lim, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 0 | |
| 2 | 2025 | 1 | |
| 3 | 2024 | 1 | |
| 4 | 2022 | 17 | |
| 5 | 2022 | 12 | |
| 6 | 2022 | 5 | |
| 7 | 2019 | 58 | |
| 8 | 2018 | 16 | |
| 9 | 2018 | 2 | |
| 10 | 2013 | 76 | |
| 11 | 2009 | 140 | |
| 12 | 2008 | 167 | |
| 13 | 2007 | 28 | |
| 14 | 2006 | 41 | |
| 15 | The majority of hepatitis B carriers are not on regular surveillance in Singapore. | 2004 | 19 |
| 16 | Initial nutritional status of stomach cancer patients. | 2002 | 2 |
| 17 | 48 weeks of adefovir dipivoxil (ADV) results in improvement in fibrosis and decreased progression of fibrosis in a double-blind, randomized, placebo-controlled study for the treatment of patients with HBeAg plus chronic hepatitis B. | 2002 | 3 |
| 18 | 2002 | 93 | |
| 19 | GS-98-437 a double-blind, randomized, placebo-controlled study of adefovir dipivoxil (ADV) for the treatment of patients with HBeAg+ chronic hepatitis B infection: 48 week results. | 2001 | 13 |
| 20 | 1993 | 19 |
About Seng Gee Lim
Seng Gee Lim is a scholar working on Hepatology, Epidemiology, Transplantation, Infectious Diseases and Gastroenterology, having authored 279 papers that have together received 14.5k indexed citations. Recurring topics across this work include Hepatitis B Virus Studies (146 papers), Hepatitis C virus research (141 papers), Liver Disease Diagnosis and Treatment (103 papers), Liver Disease and Transplantation (25 papers), Organ Transplantation Techniques and Outcomes (22 papers), Hepatitis Viruses Studies and Epidemiology (19 papers), SARS-CoV-2 and COVID-19 Research (19 papers) and Viral gastroenteritis research and epidemiology (18 papers). The work is most often cited by research in Hepatology (9.2k citations), Epidemiology (9.6k citations), Infectious Diseases (2.8k citations), Virology (306 citations) and Immunology (1.2k citations). Seng Gee Lim has collaborated with scholars based in Singapore, United States and United Kingdom. Frequent co-authors include Patrick Marcellin, Ting‐Tsung Chang, Carol Brosgart, Zachary Goodman, Yee‐Joo Tan, Wanjin Hong, Shelly Xiong, John Fry, Stephanos J. Hadziyannis and Michael Wulfsohn. Their work appears in journals such as Journal of Hepatology, Gastroenterology, Hepatology International, Journal of Virology and Liver International.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.